Satellos completes enrollment in BASECAMP Phase 2 trial of forazapadin for Duchenne

Satellos Bioscience Inc. announced on September 30, 2026 that it had completed enrollment for BASECAMP, its Phase 2 clinical trial evaluating forazapadin for Duchenne muscular dystrophy in ambulatory boys 7 to 10 years of age.¹ Forazapadin is an orally administered, small molecule drug candidate designed to restore muscle regeneration in people living with DMD, facioscapulohumeral muscular dystrophy (FSHD) and potentially other degenerative muscle diseases.¹

Chief executive Frank Gleeson said the company met and surpassed its enrollment target in less than nine months from screening its first participant.¹ He added that Satellos believes BASECAMP could support discussions with the FDA regarding a potential accelerated development pathway for forazapadin,¹ and said the company has decided to take the time necessary to compile the most complete dataset possible, adjusting its previous plan for releasing data and now intending to share topline clinical data in the first quarter of 2027.¹

The trial enrolled participants across 18 clinical sites in the U.S., Canada, Australia, Belgium, Spain, Poland and Serbia.¹ Participants were randomized 1:1:1 to receive either forazapadin 60 mg, forazapadin 120 mg or placebo.¹ The design includes a 12-week placebo-controlled period, after which participants enter a 36-week randomized active-treatment period.¹ Primary endpoints cover safety, tolerability and the effect of forazapadin on muscle force as assessed by dynamometry,¹ while secondary endpoints are meant to assess forazapadin's impact on muscle quality, function and regeneration.¹

Separately, Satellos said a Phase 2 study of forazapadin in adults with FSHD is expected to begin in the fourth quarter of 2026.¹